DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Study is currently enrolling MGMT-unmethylated Avastin (bevacizumab)-naïve recurrent GBM patients at the University of Texas MD Anderson Cancer Center VANCOUVER, British Columbia and MENLO PARK, Calif…Read More »

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results

- Company will host a business update conference call and webcast on Wednesday, February 15, 2017 at 4:30 PM EST – VANCOUVER, British Columbia and MENLO PARK, Calif., Feb.13, 2017 /PRNewswire/ — DelM…Read More »

DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Study will enroll 48 MGMT-unmethylated Avastin (bevacizumab)-naïve recurrent GBM patients VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc….Read More »

DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 9, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the de…Read More »

DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083

DelMar now holds seven allowed United States patents and eight international patents with more than 100 additional patent filings from thirteen patent families representing patent claims covering VAL-…Read More »

Forward Looking Statements

Any statements contained in this blog that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

This Blog is official and sanctioned by DelMar Pharmaceuticals, Inc.

Get DelMar Pharmaceuticals, Inc. Blog Post Alerts